Health for Life Capital II™ fund, managed by Seventure Partners, makes two new immuno-oncology (I/O) investments
9 February 2021

Health for Life Capital II™ fund, managed by Seventure Partners, makes two new immuno-oncology (I/O) investments

Seventure led $10M round for new French company focusing on I/O-microbiome and provided $3M seed funding to ErVaccine, driving an increased I/O microbiome focus in fund...

Read the press release

By continuing your browsing on this site, you accept the use of cookies to carry out statistics of anonymous visits. Read more

Authorize Refuse